News Release

The SARS-CoV-2 RBD antigen could be produced by bio-engineered plants for large-scale use in serology tests and vaccines

Peer-Reviewed Publication

PLOS

The SARS-CoV-2 RBD antigen could be produced by bio-engineered plants for large-scale use in serology tests and vaccines

image: Nicotiana benthamiana plant that is ready to be infiltrated to synthesize SARS-CoV2 antigen for use in a plant-based vaccine. view more 

Credit: Allyson MacLean, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)

Article URL:  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0277668

Article Title: Scalable agroinfiltration-based production of SARS-CoV-2 antigens for use in diagnostic assays and subunit vaccines

Author Countries: Canada

Funding: This study was funded in part by a COVID-19 Rapid Response grant by the Canadian Institute of Health Research (CIHR, #VR2 – 172722) and by a grant supplement by the Canadian Immunity Task Force (CITF) to MAL. MM holds a Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST) and YG holds a Canadian Institute of Health Research (CIHR) Frederick Banting and Charles Best graduate scholarship (CGS-M). Production of RBD was supported financially by the National Research Council Canada Pandemic Response Challenge program. Greenhouse management was supported by funding from the University of Ottawa Faculty of Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.